Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

American Urological Association In Brief

This article was originally published in The Tan Sheet

Executive Summary

"Herbal Viagra" risk: Herbal products marketed as erectile dysfunction treatments should be monitored for potentially toxic pharmacologic concentrations of PDE5 inhibitors, according to study presented at American Urological Association meeting in San Francisco May 10. Neil Fleshner, MD, et al. found significant contamination with sildenafil and tadalafil in two of seven herbal brands marketed for ED treatment. Consumers and regulatory agencies "must be aware of these findings as these agents have known fatal interactions with prevalently consumed drugs (e.g. nitrates)," according to the study. Researchers say the findings "seriously challenge the concept of safety of CAM (complimentary alternative medicine) agents" and recommend "tighter regulation of CAM marketed preparations"...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096816

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel